Targeted treatments for cervical cancer: a review

Rákkutatás · Cervical cancer

Anti‑HPV therapeutics such as 3HP‑β‑LG, carrageenan, defensins, and 25‑hydroxycholesterol are promising for cervical cancer prevention.

Cervical cancer remains a major global health threat for women, primarily driven by human papillomavirus (HPV) infection. While HPV vaccination serves as the cornerstone of prevention, disparities in vaccine accessibility persist across low‑income countries. Secondary prevention through screening faces challenges in public engagement, often leading to late‑stage diagnoses. Recent advancements in novel anti‑HPV drugs offer expanded opportunities for cervical cancer management. This review examines emerging anti‑HPV therapeutics to provide insights into innovative strategies for cervical cancer prevention and treatment. Multiple promising anti‑HPV agents have been identified, including 3‑hydroxyphthalic anhydride‑modified bovine β‑lactoglobulin (3HP‑β‑LG), carrageenan, defensins, and 25‑hydroxycholesterol (25HC). These compounds exert antiviral effects through distinct mechanisms: 3HP‑β‑LG competitively inhibits viral attachment, carrageenan blocks HPV entry via heparan sulfate mimicry, defensins inhibit the dissociation of viral capsid, and 25HC activates cholesterol‑mediated antiviral pathways. They have demonstrated strong inhibitory effects on HPV infection, making them novel therapeutic candidates for the prevention and treatment of cervical cancer.

Identifying effective anti‑HPV agents expands prevention and treatment options, addressing vaccine disparities and screening challenges, and potentially reducing the global burden of cervical cancer.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek